Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 201335 with peginterferon alfa-2a and ribavirin in HCV/HIV coinfected adults
2010-021734-59Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2011
- Modality
- Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of faldaprevir in chronic hepatitis C virus infection and Human immunodeficiency virus infection type 1, sponsored by Boehringer Ingelheim. Primary endpoint: Sustained Virological Response (SVR). Started Jun 2011; status: completed.
02
Drugs
faldaprevir
03
Conditions
chronic hepatitis C virus infectionHuman immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2010-021734-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021734-59.